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Abstract
Febrile seizures, or febrile convulsions (FEB), represent the most common form of childhood seizures and are believed to be
influenced by variations in several susceptibility genes. Most of the associated loci, however, remain ‘orphan’, i.e. the
susceptibility genes they contain still remain to be identified. Further orphan loci have been mapped for a related disorder,
genetic (generalized) epilepsy with febrile seizures plus (GEFS+). We show that both spatially mapped and ‘traditional’ gene
expression data from the human brain can be successfully employed to predict the most promising candidate genes for FEB
and GEFS+, apply our prediction method to the remaining orphan loci and discuss the validity of the predictions. For several
of the orphan FEB/GEFS+ loci we propose excellent, and not always obvious, candidates for mutation screening in order to
aid in gaining a better understanding of the genetic origin of the susceptibility to seizures.
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Introduction
Febrile seizures, or febrile convulsions (FEB), are acute
symptomatic seizures that occur in response to fever and represent
the most common form of childhood seizures, affecting worldwide
between 2 and 14% of infants before five years of age (reviewed in
[1–4]). Clinically, febrile seizures are often divided in a mostly
benign ‘simple’ type (about 60–70% of incidences), consisting of
single generalized tonic-clonic seizures of less than 10–15 minutes
without focal neurological features, and a ‘complex’ type of
prolonged seizures (15 minutes or more) with possible long-term
consequences, having focal neurological features or recurrence
within the same febrile illness [5–7]. FEB is a complex and
heterogeneous disorder in which environmental factors play an
important role, the most obvious being an immature brain
(suggested by the age-specificity) and fever. However, both
experimental data on animal models and known familial cases
with Mendelian inheritance demonstrate the significant role that
genetic factors may play in the etiology of the disease [2,3]. Several
loci have been associated with FEB predisposition and/or genetic
(generalized) epilepsy with febrile seizures plus (GEFS+) [8,9],
often with an autosomal dominant mode of inheritance with
incomplete penetrance, suggesting a possibly simultaneous in-
volvement of multiple genes [1,10]. However, so far only few
susceptibility genes have been found [11].
Although FEB is considered to be a distinct syndrome with a
generally very good prognosis, and not a true epileptic disease, some
evidence points towards a higher risk of patients with a FEB history
to develop epileptic disorders later in life [1–4,7,12]. While most
prospective studies have found no evidence for this hypothesis,
retrospective studies indicate that a high fraction of patients that
require surgery for treatment-resistant temporal lobe epilepsy (TLE)
have a history of FEB, and large cohort studies have linked a history
of FEB to a greater than five-fold increase in epilepsy later in life,
although the overall probability of the latter event remains low.
Moreover, mutations in the genes encoding for the voltage-
gated sodium channel a-1, a-2 and a-9 subunits ( SCN1A, SCN2A
and SCN9A) and the GABAA receptor c-2 subunit gene
( GABRG2)–four out of five known FEB susceptibility genes
according to the OMIM database (see Table 1)–have been
identified in families with GEFS+. In many of the reported cases of
familial FEB, at least some of the affected members developed also
epileptic seizures [1], suggesting that many FEB loci actually
represent genetic loci for GEFS+ [11]. Only the FEB2, FEB5 and
FEB8 loci have been reported for pure febrile convulsions [13–15]
(although the gene for FEB8, GABRG2, has also been found
mutated in GEFS+ [16]). This may, of course, reflect only the
appearance of febrile seizures in GEFS+, as a continuum between
febrile and afebrile seizures is typical of GEFS+ [1]. On the other
hand, it may also hint at a more profound relation between FEB
and true epileptic disorders.
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23149Although the association of FEB with an increased risk of adult
epileptic disorders such as TLE remains controversial [1,17],
febrile seizures can lead to epilepsy in some animal models,
probably due to an imbalance of excitation and inhibition in the
limbic system [4]. Due to the obvious differences between animal
models and FEB in humans (see [2,4] for a discussion), however,
the interpretation of the obtained results requires some caution.
On the other hand, direct human studies of the mechanisms
underlying FEB have obvious limitations. In this report, we try to
aid in elucidating the genetic factors that influence FEB by
applying computational disease gene prioritization to evaluate the
‘positional’ candidate genes in previously mapped ‘orphan’ FEB
and GEFS+ loci (listed in Table 2), for which the involved
susceptibility genes have not yet been determined. We first show
that both spatially mapped and ‘traditional’ gene expression data
from the human brain can be successfully used to prioritize
candidate genes for Mendelian disorders related to the central
nervous system (CNS), and that the results obtained for the two
data sources are highly complementary. We then demonstrate that
this works particularly well for ‘re-discovering’ known FEB/
GEFS+ susceptibility genes, suggesting that a prioritization of the
candidate genes included in orphan loci may actually yield
biologically meaningful predictions. Finally, we apply the method
to all orphan FEB and GEFS+ loci and present the most promising
candidates. We hope that our predictions may eventually help in
gaining a better understanding of the genes that influence the
susceptibility to seizures.
In our previous proof-of-concept study [18] we have shown that
spatially mapped, i.e. 3D, high-resolution gene expression data
covering the entire adult brain of the C57BL/6J mouse strain–the
anatomically comprehensive Allen Mouse Brain Atlas (MBA)
[19]–can be successfully exploited for the prioritization of
positional candidates for both mouse phenotypes and human
CNS-related hereditary disorders. This particular type of gene
expression data is distinct from ‘traditional’ heterogeneous datasets
containing samples from multiple tissues and cell types, due to its
three-dimensional geometry and tissue-specificity. We have used
this dataset to suggest some promising novel candidates for X-
linked mental retardation [18].
However, the important differences between human FEB and
animal models of the disorder [2,4], and the fact that differences
between mouse models and human brains can yield important
insight also for other neurological disorders [20], suggest that an
application of our method to the Allen Institute’s recently
published Human Brain Atlas (HBA) [21] may be more
appropriate, even if the HBA is still in a preliminary version.
In contrast to the more complete MBA, the HBA is not derived
from in situ hybridization (ISH) images of many different brains,
but instead uses a microarray technology on samples from a single
individual. It does not yet provide expression data for all
consecutive positions of the entire organ since the project is
scheduled to be completed in 2013. Nonetheless, the current
preliminary version already includes samples for most of the
anatomical structures of the human brain.
Results
Evaluation for all CNS-related disorders
We evaluated the possibility to predict gene–phenotype
associations based on 13,204 HBA-derived 3D gene expression
profiles from the human brain using a large-scale leave-one-out
cross validation (LOOCV; see Methods) over all CNS-related
Mendelian disorders from the Online Mendelian Inheritance in
Man (OMIM) database [22] (see Text S1) and compared the
results to those previously obtained for the MBA [18].
As in our previous study, we prioritized a list of candidate genes
taken from ‘‘artificial’’ orphan loci of various sizes centered around
the true phenotype-causing gene g and verified how often g was
ranked first (Rg~1), among the top ten (Rgƒ10), and among the
upper 10% (Rrel
g ƒ0:1) of the candidates. For this purpose, the 3D
gene expression profiles of the candidates were compared to those
of a set of disease-related reference genes (see Methods).
As can be seen in Table S2, the procedure yielded for all sizes of
artificial loci a significantly higher number of positive results than
expected by chance, suggesting that spatial gene expression data
from the HBA can be an important source of information to
predict novel gene–phenotype associations. The HBA expression
profiles perform similarly to those of the MBA, in some cases even
better. This may seem obvious, given that we consider human
disorders, but it is less clear when taking into account that the
mouse 3D expression profiles cover the entire brain and have a far
higher-resolution than the preliminary human data and that the
two brain atlases are based on completely different technologies
(ISH vs. microarray).
Better results are obtained when taking the known molecular
basis of the disorders as reference (simulating phenotypes with
partially known molecular basis), instead of relying on reference
genes from similar OMIM phenotypes (to simulate phenotypes
with unknown molecular basis; see Text S1). Nonetheless, the
results obtained when simulating an unknown molecular basis are
highly significant and suggest that the method can be used also
for phenotypes to which so far no disease genes have been
associated.
Complementarity of HBA and GEO data
Since the HBA is based on microarray technology, in contrast to
the MBA that uses ISH, we asked how the disease gene
prioritization method performs using ‘traditional’ microarray data
from multiple individuals. For this purpose we compiled a dataset
of 453 normal brain samples for 19,946 genes from the Gene
Expression Omnibus (GEO) [23].
The GEO dataset performs better than the HBA data (see
Table S2). This is likely due to the greater number of genes for
which expression profiles are available. Nonetheless, given the
different nature of the two datasets the positive predictions derived
from both have only a limited overlap (no overlap for Rg~1 and
less than 30% for both Rgƒ10 and Rrel
g ƒ0:1; see Table S3). This
suggests that the 3D gene expression data–spatially distributed
Table 1. Genes known to be involved in FEB and/or GEFS+.
Gene Entrez ID Phenotype(s) OMIM ID(s) Locus References
GABRD 2563 GEFS+5 #604233 1p36.3 [77]
GABRG2 2566 FEB8, GEFS+3 #611277,
#604233
5q34 [13,16,78,79]
SCN1A 6323 FEB3A, GEFS+2 #604403,
#604233
2q24.3 [80–83]
SCN1B 6324 GEFS+1 #604233 19q13.1 [84]
SCN2A 6326 FEB/GEFS+ (–)
{ 2q24.3 [85]
SCN9A 6335 FEB3B, GEFS+7 #604403,
#604233
2q24 [86]
{SCN2A is not listed in OMIM as a FEB or GEFS+ gene, but is usually considered
as such [3,10,11].
doi:10.1371/journal.pone.0023149.t001
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complementary to that provided by ‘traditional’ expression data–
arbitrarily distributed samples from many individuals. Also the fact
that different microarray platforms have been used for the two
datasets is likely to play a role [24].
Consequently, some cases can be successfully predicted
when relying on spatial expression information while others
using ‘traditional’ expression data. We therefore suggest that
while the best candidates are those derived from an
intersection of the prioritizations from the two data sources,
those candidates obtained from only one of the datasets should
still be taken into consideration. Although the GEO dataset
performs generally better, it cannot replace the HBA
predictions.
Evaluation for FEB and GEFS+
The effectiveness of our approach for CNS-related disease
phenotypes in general does not necessarily imply that it can be
successfully used for FEB and GEFS+ in particular. Febrile
seizures are age-dependent and occur in immature brains of
infants and young children. It is therefore imperative to specifically
evaluate whether in this case expression data from the adult brain,
that shows important differences in gene expression patterns, can
aid in prioritizing candidate genes.
In order to verify the performance of our approach for the
specific case of FEB and GEFS+, we performed an LOOCV
taking into account only the reference genes listed in Table 1,
found to be associated with FEB and GEFS+ in OMIM and/or
the literature. From this list, we excluded MASS1 ( GPR98)t h a t
was suggested by Nakayama et al [25] to be the disease gene for
the FEB4 locus because the gene had been reported to be
involved in audiogenic seizures in the Frings mouse strain [26,27]
and they found a nonsense mutation in a small family with febrile
and afebrile seizures. However, the cosegregation of the mutation
with the seizure phenotype was not unambiguous due to the small
family size. Moreover, another linkage study has mapped FEB/
GEFS+ to an overlapping (although larger) locus, but did not find
disease-causing mutations in the exons of MASS1 (or VLGR1 that
includes most MASS1 exons), suggesting that another gene may
be underlying the FEB4 locus [28]. Due to this uncertainty, we
chose to consider this linkage interval as an additional orphan
locus (see Table 2) and MASS1 as a candidate, rather than a
disease gene.
As for the large-scale LOOCV performed over all CNS-related
disorders, we constructed artificial loci of various sizes centered
around each of the FEB or GEFS+ genes and took the remaining
five genes as reference genes for the prioritization.
Table 3 demonstrates that in most of the prioritizations the true
FEB/GEFS+ gene is ranked among the top ten and/or the best
10% of the candidates from the artificial locus. Most important,
four of the six genes ( GABRD, GABRG2, SCN1B, and SCN2A) rank
in at least one of the two datasets among the first three candidates
for artificial loci of similar sizes (N =50) as the orphan loci
(between 12 and 112 genes, see Table 2). Even for far larger loci of
up to 401 candidates (N =200) half of the disease genes have
Rgƒ3, suggesting that the method may be particularly effective
for FEB and GEFS+.
Although, as for the large-scale LOOCV, the GEO expression
data generally performs better, in some cases the rankings
obtained with the HBA data are better. Interestingly, this is the
case for SCN9A that does not show a particularly strong
relationship with the other reference genes, but whose involvement
in FEB/GEFS+ is significantly better recalled when applying
spatially mapped expression profiles.
Table 2. Orphan FEB and GEFS+ loci.
Phenotype OMIM ID Locus Coordinates Candidates Ref.
total HBA GEO
FEB1 %121210 8q13-q21 chr8:66,932,638–72,988,347 31 19 28 [29]
FEB2 %602477 19p13.3 chr19:3,075,844–7,583,551 112 76 105 [14]
FEB4
{ #604352 5q14-q15 chr5:89,166,516–110,036,710 50 39 49 [40]
FEB4 #604352 5q14.3-q23.1 chr5:88,728,695–122,125,234 93 70 88 [28]
(Deprez et al.)
{
FEB5 %609255 6q22-q24 chr6:129,947,710–133,546,636 29 12 27 [15]
FEB6 %609253 18p11.2 chr18:10,133,108–12,597,248 12 11 12 [52]
FEB7 %611515 21q22 chr21:32,533,246–39,359,893 59 43 54 [58]
FEB9 %611634 3p24.2-p23 chr3:24,924,673–33,687,557 32 26 29 [53]
FEB10 %612637 3q26.2-q26.33 chr3:170,902,825–181,419,957 28 24 28 [63]
GEFS+4 %609800 2p24 chr2:17,491,922–20,329,508 13 8 11 [67]
GEFS+6 %612279 8p23-p21 chr8:6,940,747–15,649,945 56 20 36 [72]
GEFS+6 %612279 8p23.1-p21.3 chr8:6,940,747–20,367,401 79 35 59 [72]
(family 15173)
*
GEFS+N – 6q16.3-q22.31 chr6:101,352,134–119,553,944 89 60 85 [73]
Mapped FEB and GEFS+ loci for which the susceptibility or disease-causing gene has not yet been identified. Coordinates correspond to the regions flanked by genetic
markers identified in the respective studies. The number of candidate genes in the mapped regions is indicated as a total number and the subset of genes for which
HBA and GEO expression profiles are available, respectively (see Table S4 for the complete lists of candidates). Note: ‘‘GEFS+N’’ is not an official symbol (N=novel).
{The implication of MASS1 in FEB4 [25] is controverse; Deprez et al [28] describe a case with an overlapping linkage interval (
{) without evidence for MASS1 mutations
(see text).
*Baulac et al [72] describe also a family with a larger linkage interval; since it is not clear whether the genetic cause is the same, we consider this interval as a distinct
orphan locus.
doi:10.1371/journal.pone.0023149.t002
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Given the good performance of our prioritization procedure, as
demonstrated by the CNS-related and the GEFS+/FEB-specific
LOOCVs, we processed all orphan disease loci (see Table 2) to
find the most promising candidates for an involvement in FEB or
GEFS+ susceptibility using only the known disease genes (Table 1)
as reference genes.
Since we found the HBA and GEO expression data to be
complementary for the purpose of disease gene prediction for
CNS-related disorders, in Table 4 we report for all orphan loci the
best ranking candidate for each of the two data sources, as well as
the candidate that has the best average relative rank (average of
Rrel
g ) over both datasets. For the complete prioritized candidate
lists that contain further interesting candidates, please see Table
S4.
Strikingly, for most of the orphan loci, the results obtained with
HBA and GEO data support each other. Indeed, in the large
majority of cases, the first ranking candidate of one data source
often obtained a high rank also for the other data source and vice
versa, so that one of the two first ranking candidates (from HBA or
GEO) remains the best candidate also on average. Only for four of
the thirteen loci (FEB2, both FEB4 loci, and FEB5) the best
average candidate did not rank first for HBA or GEO. Most
important, for several of the loci (FEB6, GEFS+4, GEFS+6, and
GEFS+N), both spatially mapped and traditional expression data
agree upon the best candidate. This result is especially remarkable
for the GEFS+N locus, being the third largest orphan locus with a
total of 89 candidates (see Table 2).
Discussion
Overall, the good agreement between the prioritizations for
FEB/GEFS+ obtained starting from HBA and GEO expression
data increases the likelihood that the best candidates are
functionally correlated to known FEB and GEFS+ genes and thus
potentially disease relevant. Therefore, in the following sections we
discuss particularly interesting candidates for the known orphan
loci.
FEB1
The first FEB locus was mapped by Wallace et al [29] in a large
Australian family spanning three generations. Results supported a
hypothesis of autosomal dominant inheritance with incomplete
penetrance, i.e. conditional upon the involvement of other
modifier loci or environmental factors.
Wallace et al [29] have proposed corticotropin-releasing
hormone (CRH) as one of the most interesting candidates of this
locus. Indeed, in our prioritizations, CRH ranks 4th for the HBA
expression data and 2nd for GEO, as well as 2nd with respect to
the average relative rank over both datasets (see Table S4). CRH is
known to be involved in an age-dependent manner in seizures in
rat models [30,31] and its activation is thought to be an important
mechanism for generating developmentally regulated, triggered
seizures [32]. Notably, some studies support a region-specific
regulation of CRH gene expression by gamma-aminobutyric acid
(GABA). Tran et al [33], for example, showed that the GABA
degradation blocker gamma-vinyl-GABA (VGB) that is used for
clinical seizure treatment causes a reduction of both CRH gene
expression and secretion in the hypothalamus of 9-day-old rats.
Finally, an excess in CRH has been hypothesized to underlie West
syndrome, in which seizures during infancy play an important role
[34], and CRH has been found to play a role in the increased
susceptibility to seizures in shigellosis [35].
Taken together, CRH is a likely candidate for this locus, and a
mutation that causes an increase in CRH levels or activity would
be consistent with an autosomal dominant inheritance. Our two
first ranking candidates ARFGEF1 and VCPIP1, instead, have so
far not been implicated in seizures or epileptic disorders, but their
coexpression with the reference genes in the human brain suggests
a potential functional relationship.
FEB2
Johnson et al [14] mapped the FEB2 locus in a large multi-
generational family with an autosomal dominant inheritance of
febrile convulsions.
A potentially interesting candidate for the largest FEB/GEFS+
orphan locus is the ATCAY gene, which has been found mutated in
human Cayman ataxia [36] and in a form of rat dystonia [37].
This gene ranks 5th for the HBA expression data and 3rd for
GEO, as well as 4th with respect to the average relative rank over
both datasets (see Table S4). ATCAY encodes for BNIP-H or
Caytaxin, a brain-specific member of the BNIP-2 family that
reduces the steady-state levels of glutamate by inhibiting kidney-
type glutaminase (KGA) enzyme activity, affecting glutamate
Table 3. Leave-one-out cross-validation of known FEB and
GEFS+ genes.
Gene gN HBA GEO
Rg Rrel
g Rg Rrel
g
GABRD 50 3??? 0.0435 2??? 0.0217
100 5? 0.0467 3??? 0.0210
200 6? 0.0390 3??? 0.0140
400 10? 0.0357 4? 0.0101
GABRG2 50 3??? 0.0455 4? 0.0421
100 4? 0.0294 4? 0.0214
200 6? 0.0287 4? 0.0134
400 9? 0.0257 4? 0.0082
SCN1A 50 12 0.1644 4? 0.0404
100 28 0.2137 6? 0.0319
200 42 0.1615 6? 0.0164
400 72 0.1426 9? 0.0126
SCN1B 50 3??? 0.0448 1??? 0.0105
100 8? 0.0541 1??? 0.0054
200 18 0.0629 3??? 0.0082
400 39 0.0721 5? 0.0069
SCN2A 50 7? 0.1000 2??? 0.0202
100 8? 0.0611 3??? 0.0160
200 10? 0.0385 3??? 0.0082
400 12 0.0237 3??? 0.0042
SCN9A 50 8? 0.1111 65 0.6566
100 12 0.0923 118 0.6277
200 20 0.0769 230 0.6284
400 27 0.0536 459 0.6411
Absolute (Rg) and relative (Rrel
g ) rankings of the known FEB and GEFS+ genes g
(see Table 1) for LOOCVs using different artificial locus sizes N (up to 2N+1
genes). Results are shown for both gene expression datasets, HBA and GEO.
Ranks among the best 10% (Rrel
g ƒ0:1) are evidenced by bold face font. Ranks
among the top 10 (Rgƒ10) are additionally marked by a single star (?)a n d
ranks among the top 3 (Rgƒ3) by three stars (??? ).
doi:10.1371/journal.pone.0023149.t003
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function of ATCAY may lead to deregulated glutamatergic
activation or even to glutamate excitotoxicity [38]. Hence, we
propose that a mutation of the ATCAY gene may potentially lead
to an imbalance between excitation and inhibition that increases
the susceptibility to seizures.
The coexpression of BRUNOL5,o rCELF5, with the reference
genes is also intriguing. Indeed, this gene encodes for a brain-
specific splicing factor (although its function is likely not limited to
the regulation of alternative splicing) [39] that may in theory affect
the splicing of other genes related to FEB/GEFS+.
FEB4
We have considered two different linkage intervals for FEB4,
since Deprez et al [28] mapped a locus that overlapped the one
first identified by Nakayama et al [40], who had suggested MASS1
( GPR98) as the disease causing gene [25]. The evidence, however,
was not conclusive and Deprez et al [28] did not find any disease-
causing mutations in the exons of MASS1 (see above), so that we
considered it as a regular candidate.
In our prioritization for the original FEB4 locus, GPR98 ranks
16th and 20th for HBA and GEO expression data, respectively. In
the larger locus identified by Deprez et al [28] the ranks are even
less suggestive (31st for HBA and 39th for GEO, see Table S4).
Hence, at least with respect to expression profiles in the human
brain, as compared to those of the reference genes, MASS1 does
not seem to be a particularly strong candidate. Of course this result
does not imply that this gene is not involved, as we do not expect
all disease genes to be revealed by a coexpression-based approach.
Its involvement in audiogenic seizures in the Frings mouse strain
[26,27] remains a strong argument for a possible implication in
FEB/GEFS+.
However, among the other candidates found in these overlap-
ping loci, we think that the peptidylglycine a-amidating monoox-
ygenase ( PAM) gene is a particularly promising alternative.
Indeed, although PAM is not a very strong candidate with the
HBA dataset, it is the top scoring candidate in both intervals with
the GEO dataset. The protein encoded by the PAM gene is a
cuproenzyme essential for the synthesis of many neuropeptides
[41]. Finally, and quite remarkably, it has recently been shown
that mice heterozygous for a null mutation in the PAM gene are
Table 4. Prediction results for orphan FEB and GEFS+ loci.
Phenotype / Candidate HBA GEO average
Orphan locus Entrez ID Symbol Rg Rrel
g Rg Rrel
g Rrel
g
FEB1 10565 ARFGEF1 1 0.0526 19 0.6786 0.3656
FEB1 80124 VCPIP1 3 0.1579 1 0.0357 0.0968
FEB2 56961 SHD 1 0.0132 8 0.0762 0.0447
FEB2 60680 BRUNOL5 3 0.0395 1 0.0095 0.0245
FEB2 79187 FSD1 2 0.0263 2 0.0190 0.0227
FEB4 2745 GLRX 1 0.0256 10 0.2041 0.1149
FEB4 5066 PAM 17 0.4359 1 0.0204 0.2282
FEB4 1946 EFNA5 4 0.1026 2 0.0408 0.0717
FEB4 (Deprez et al.) 9315 C5orf13 1 0.0143 12 0.1364 0.0753
FEB4 (Deprez et al.) 5066 PAM 33 0.4714 1 0.0114 0.2414
FEB4 (Deprez et al.) 814 CAMK4 4 0.0571 2 0.0227 0.0399
FEB5 9465 AKAP7 1 0.0833 7 0.2593 0.1713
FEB5 114801 TMEM200A 3 0.2500 1 0.0370 0.1435
FEB5 285735 LOC285735 - - 2 0.0741 0.0741
FEB6 8774 NAPG 1 0.0909 1 0.0833 0.0871
FEB7 3763 KCNJ6 1 0.0233 2 0.0370 0.0301
FEB7 7074 TIAM1 20 0.4651 1 0.0185 0.2418
FEB9 7342 UBP1 1 0.0385 2 0.0690 0.0537
FEB9 25827 FBXL2 10 0.3846 1 0.0345 0.2095
FEB10 5290 PIK3CA 1 0.0417 3 0.1071 0.0744
FEB10 57552 AADACL1 2 0.0833 1 0.0357 0.0595
GEFS+4 7447 VSNL1 1 0.1250 1 0.0909 0.1080
GEFS+6 157627 LOC157627 1 0.0500 1 0.0278 0.0389
GEFS+6 (family 15173) 286097 EFHA2 1 0.0286 2 0.0339 0.0312
GEFS+6 (family 15173) 157627 LOC157627 2 0.0571 1 0.0169 0.0370
GEFS+N 7259 TSPYL1 1 0.0167 1 0.0118 0.0142
For each orphan FEB or GEFS+ locus (see Table 2) we report the best ranking candidate gene for HBA expression data, for GEO expression data and the candidate gene
with the best average Rrel
g (indicated by bold face font). For the complete prioritized candidate lists, see Table S4. Rg = absolute rank; Rrel
g = relative rank (among
candidates with expression profiles). Note: ‘‘GEFS+N’’ is not an official symbol (N=novel).
doi:10.1371/journal.pone.0023149.t004
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together, these evidences point to PAM as a very strong candidate
for FEB4.
But also GLRX and C5orf13 are potentially interesting
candidates. Glutaredoxin (thioltransferase), or GLRX, regulates
the activity of the copper-transporting P-type ATPases ATP7A
and ATP7B [43] that are involved in Menkes disease (OMIM:
#309400) and Wilson disease (OMIM: #277900), respectively.
Since epilepsy is a major feature of Menkes disease [44,45], and
seizures occur at low frequency in patients affected by Wilson
disease [46,47], it is conceivable that reduced function of GLRX
may lead to increased neuronal excitability. On the other hand,
C5orf13 (also PTZ17 or P311) lies outside of the original FEB4
locus but might be a candidate for the larger locus reported by
Deprez et al [28], since it was identified as differentially expressed
after inducing seizures in mice [48]. However, no seizures were
reported in C5orf13 knockout mice [49].
FEB5
Nabbout et al [15] suggested that the locus mapping to 6q22-
q24 was the first locus identified for pure simple febrile seizures,
the most frequent form of FEB. They excluded the implication of
several candidate genes, such as syntaxin 7 ( STX7), A kinase
anchor protein 7 ( AKAP7, also AKAP18), putative neurotransmitter
receptor ( PNR), G protein receptor 58 ( GPR58) and G protein
receptor 57 ( GPR57) by sequencing their coding exons and exon–
intron boundaries.
According to our analysis, AKAP7 is one of the best candidates,
ranking 1st for the HBA. AKAP7, that is expressed among other
tissues in the cerebral cortex, targets the cAMP-dependent protein
kinase (PKA) to the plasma membrane, permitting its functional
coupling with L-type calcium channels [50]. These voltage-gated
channels control a variety of neuronal functions that are
implicated in epileptogenesis [51]. It is in principle possible that
the affected family members studied by Nabbout et al [15] are
carriers of a mutation that effects regulatory elements or other
essential non-coding residues of AKAP7. Hence, we suggest not to
exclude the possibility that a mutation in AKAP7 is the true cause
for the FEB5 locus.
FEB6
The haplotype analysis performed by Nakayama et al [52]
indicated a possible role for the IMPA2 gene, which is located in
the FEB6 locus. Moreover, Nabbout et al [53] have found a locus
on chromosome 18p to contain a modifier gene who’s cosegrega-
tion with the FEB9 locus on 3p (see FEB9) is associated with more
severe disorders like childhood absence epilepsy (CAE) and TLE,
but is likely to also contribute to febrile seizures per se [53],
suggesting that the modifier locus could actually be the FEB6
locus. Thus, they sequenced the IMPA2 gene as most likely
candidate, but found no disease-causing mutations. In our
analysis, IMPA2 has no significant rankings (5th out of 11 for
HBA and 8th out of 12 for GEO expression data). However,
neither the lack of mutations in [53] nor our negative result
represent sufficient evidence to exclude this candidate.
The best candidate identified by our approach is the N-
ethylmaleimide-sensitive factor attachment protein gamma
( NAPG) that ranks first with both the HBA and the GEO datasets.
The encoded protein belongs to the SNAP family, a group of
factors involved in membrane fusion events by allowing NSF
proteins to target membranes. Accordingly, the NAPG protein has
been shown to mediate platelet exocytosis and to control the
membrane fusion events of this process [54]. Although the gene
has never been studied in a neuronal context, genetic studies
suggest that it could play an important role in neurons, because a
possible involvement in bipolar disorders has been detected by
several independent reports [55–57].
FEB7
The orphan FEB7 locus was mapped by Hedera et al [58] in a
five-generation family with autosomal dominant febrile seizures.
Of 13 individuals affected by FEB, three showed coexisting
afebrile seizures. The authors sequenced all exons of four ion-
channel genes–the potassium channel genes KCNE1, KCNE2 and
KCNJ6 and the intracellular chloride channel gene CLIC6–but did
not identify any disease-causing mutations. Three of these
candidates ( KCNE1, KCNE2 and CLIC6) have no HBA expression
profiles available, but rankings obtained with the GEO dataset are
rather low (37th, 26th and 36th out of 54, respectively). KCNJ6,
however, was ranked 1st for the HBA expression data and 2nd for
GEO. As for AKAP7 and FEB5, a mutation in a regulatory
element or in another essential non-coding region should not be
excluded.
On the other hand, even the TIAM1 gene, that ranks first with
the GEO dataset, could be an interesting candidate, because
studies conducted in rodents have shown that the encoded protein
plays a role in axonogenesis [59], in neuronal migration [60] and
in the formation of dendritic spines [61].
FEB9
Nabbout et al [53] mapped the FEB9 locus in a large French
family with febrile seizures but also CAE and TLE that were
largely associated with an additional modifier locus on chromo-
some 18p (see FEB6). The authors have sequenced the coding
exons, exon-intron boundaries and translation start sites of six
potential candidates of the FEB9 locus without finding disease-
causing mutations. Of these, the SCL4A7 gene encoding the
sodium bicarbonate cotransporter NBC3 scored best in our
prioritizations (3rd for HBA, 10th for GEO and 5th for its average
relative rank).
The two candidates that rank first for HBA and GEO data,
respectively, are difficult to link to FEB or GEFS+.
However, GPD1L, which ranks 5th for HBA, 3rd for GEO, and
3rd with respect to its average relative rank, encodes the glycerol
phosphate dehydrogenase 1-like protein, an enzyme that may
modify heart excitability by regulating the activity of the sodium
channel SCN5A through PKC-dependent phosphorylation [62].
SCN5A itself was one of the candidates sequenced by Nabbout et al
[53] (although it lies for about 5-Mb outside of the FEB9 locus),
but had no causal mutations. It is in principle thinkable that
GPD1L instead may be responsible for the phenotype through its
capability to regulate the activity of SCN5A or other sodium
channels in the brain, some of which have already been implicated
in FEB/GEFS+ (see Table 1).
FEB10
Dai et al [63] mapped the FEB10 locus in a four-generation
Chinese family with autosomal dominant febrile seizures and
epilepsy. By mutational analysis, they have excluded the two
potassium channel genes KCNMB2 and KCNMB3, none of which
ranks among the top five in our analysis (average relative rank over
HBA and GEO).
The strongest candidates identified by our analysis are
AADACL1 and PIK3CA that rank very favorably with both
datasets. The involvement of the first gene is not supported by
other evidences, because AADACL1, also known as NCHE1
(neutral cholesterol ester hydrolase 1), has never been studied in a
neuronal context. On the other hand, PIK3CA, the p110 alpha
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factor-activated signaling and for its oncogenic potential, has
recently been shown to negatively regulate neuronal excitability
[64]. In addition, levels of phosphorylated (inactive) FOXO, a
product of PI3K/Akt activity, are strongly modulated in
experimental models of epilepsy and in the hippocampi of
epileptic patients [65]. Finally, it has been recently observed that
application of leptin, a known PI3K activator, inhibits seizures in
rats in a PI3K-dependent manner [66]. Thus, it is conceivable that
mutations leading to reduced PI3K activity might be a cause of
increased neuronal excitability, possibly leading to febrile seizures.
GEFS+4
Audenaert et al [67] have suggested that KCNS3 (voltage gated
potassium channel, subfamily S, member 3) is one of the most
attractive candidate genes in the GEFS+4 locus, since it encodes a
subunit of the voltage-gated potassium channel of the delayed
rectifier type and is abundantly expressed in the brain [68]. We
find this gene ranking 3rd for HBA and 6th for GEO (5th with
respect to its average relative rank), but given the small locus size,
these ranks cannot be deemed as very significant.
According to our prioritization, we propose VSNL1 (also VILIP-1)a s
a potential alternative candidate. Indeed, besides ranking first for both
the HBA and the GEO dataset, this gene may be strongly involved in
regulating neuronal excitability. VSNL1 is a member of the visinin/
recoverin subfamily of neuronal calcium sensor proteins [69].
Interestingly, it has been recently found that VSNL1 may lead to
the upregulation of functional a4b2 nicotinic acetylcholine receptors
(nAChR) in hippocampal neurons [70]. This observation could be
very important, because a dysfunction of the a4b2 nAChR has been
previously implicated in frontal lobe epilepsy [71]. Therefore, a
mutation that should result in increased function of VSNL1 would be
predicted to produce increased neuronal excitability.
GEFS+6
The locus for GEFS+6 was mapped by Baulac et al [72] in two
independent French families. More precisely, the largest family
(family 15173) showed a linkage to a 13-Mb interval between
markers D8S1706 and D8S258 (chr8:6,840,747-20,367,401), but
since a second family showed a linkage to an overlapping region,
the authors assumed that in both families the same gene was
affected and hence narrowed to region down to a 7.3-Mb
candidate interval (chr8:6,940,747-15,649,945).
However, it is in principle possible that the genetic causes are
distinct for the two families and hence we have performed the
prioritization for both intervals. The results of these prioritizations
are in good agreement, since the top three genes (with respect to
average relative rank) for the narrow locus– LOC157627, MTMR9,
PRAGMIN–rank 2nd, 4th, and 3rd for family 15173, respectively
(see Table S4). LOC157627 is the best ranking gene for GEO in
both the narrowed and the larger locus. EFHA2, although lying for
about 1.2-Mb outside of the narrowed GEFS+6 locus, has
particularly good rankings for the locus of family 15173 (1st for
HBA, 2nd for GEO, and 1st regarding the average relative rank)
and might thus be taken as an additional interesting candidate.
Baulac et al [72] have sequenced the coding exons of six
candidates– MTMR9, MTMR7, CTSB, SGCZ, SG223 ( PRAGMIN),
and ATP6V1B–according to their expression in the brain and
putative function, but all identified variants were either known
polymorphisms or found in 100 matched French controls. Two of
these candidates are suggested as interesting by our analysis:
MTMR9 and PRAGMIN (see Table S4). Their rankings for the
larger locus of family 15173 are less suggestive, but still good. It is
in principle possible that mutations in their regulatory elements or
other essential non-coding regions are causative for GEFS+.
Therefore, we suggest not to exclude them from further studies.
GEFS+N
Not having found an official denomination, we called this locus
‘‘GEFS+N’’ (where N stands for ‘novel’). The locus contains no
known genes associated with ion channels or neurotransmitter
receptors, therefore Poduri et al [73] suggest that the identification
of the responsible gene may lead to novel insight into the
mechanisms of febrile seizures and inherited epilepsy. This makes
our prediction results for this locus particularly interesting, but also
more difficult to interpret, since a coexpression with known disease
genes (reference genes) is more likely if a candidate is involved in a
similar function.
Of the 16 candidates sequenced and excluded by Poduri et al
[73], KPNA5 obtained the highest average relative rank in our
prioritization (9th for HBA, 11th for GEO, 7th with respect to the
average relative rank).
The TSPYL1 and TSPYL4 genes come out as outstanding
candidates from our analysis. Indeed, they are found as the first
and second ranking genes, respectively, for both the HBA and
GEO dataset; a very strong result if considering that the locus
contains a total of 89 candidates. The two genes are closely related
members of the Nucleosome Assembly Protein (NAP) family. Both
genes have been investigated as candidates for a genetic syndrome
characterized by sudden infant death from cardiac and respiratory
arrest, associated with dysgenesis of the testes, and null mutations
have been found in TSPYL1 [74]. However, the molecular
mechanism leading to this phenotype is not understood.
Therefore, we think that it would be very interesting to evaluate
both genes for mutations in GEFS+N. Moreover, it could be worth
addressing whether increased or decreased function of these genes
may affect the electrical behavior of excitable cells, such as
neurons and cardiomyocytes. These studies could contribute to
elucidating the mechanisms underlying both febrile seizures and
sudden death syndrome.
Conclusions
In this study, we have shown that the preliminary Human Brain
Atlas (HBA), although not yet complete, is already a powerful tool
for disease gene prediction and provides results that are comple-
mentary to those obtained from a traditional microarray dataset.
Despite the fact that the HBA and GEO gene expression data
represent mostly the adult brain and not the immature brain, an
application to FEB/GEFS+ seemed particularly promising, given
that, in an LOOCV with artificial loci of approximately the same
size as the largest FEB or GEFS+ orphan loci, four out of six known
diseasegenesrankedamongthefirstthreecandidatesforatleastone
of the two human brain gene expression atlases. This allowed us to
propose several strong candidates for the true orphan loci and to
discuss their possible involvement in FEB/GEFS+. Several of them
would be excellent candidates formutationscreenings,however also
high ranking candidates that are less obviously related to neuronal
excitability should not be excluded from further analysis. In fact, the
purpose and strength of computational approaches like the one
presented here is to potentially uncover so far unknown and non
obvious functional relationships.
Methods
Spatial human brain gene-expression data
We downloaded the spatial gene-expression data of the Human
Brain Atlas (HBA) from [21] on 20 July 2010, but used only the
most recent experiment for each tissue ID, resulting in a total of
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cess’’ Bioconductor R package, we mapped the probesets of the
custom Agilent 8x60 Whole Human Genome array (that is derived
from the standard Agilent 4x44 Whole Human Genome array) to
Entrez gene IDs via the RefSeq RNA nucleotide accessions
reported in the downloaded data files. We considered only unique
mappings to Entrez IDs and averaged expression profiles of genes
with multiple probesets, obtaining expression profiles for a total of
13,204 genes.
Traditional microarray expression data
For comparison with the spatially mapped gene expression data
we compiled a microarray dataset from GEO [23], containing 453
samples of normal human brain tissue (excluding tumor samples or
other diseases) performed on a standard Affymetrix HG-U133
Plus 2.0 chip. We chose the Affymetrix platform over the Agilent
4x44 because for the latter only four normal brain samples were
available. A list of the GEO accessions of all samples can be found
in Table S1. We normalized the dataset with the Affymetrix
MAS5.0 algorithm and mapped probeset IDs to Entrez IDs using
the official Affymetrix annotation (na30), but accepted only
probesets with unique Entrez IDs (19,946 genes). For genes with
multiple probesets, we used averaged expression profiles.
Candidate gene prioritization
The evaluation and prioritization of positional candidates was
performed as in our previous study. The following is a brief
summary of the procedure, for a more detailed description, please
see [18].
First, a set of ‘reference genes’ is defined as the genes that are
involved in the given phenotype or in similar phenotypes (see Text
S1). Then, for each reference gene, all other genes are ranked in a
genome-wide coexpression list according to their decreasing
Pearson correlation coefficient with the reference gene.
The relative ranks of the positional candidates within these
reference coexpression lists are determined (i.e. the ranks divided
by the number of genes in the lists) and overall scores for the single
candidates are determined as the product of their relative ranks.
Finally, positional candidates are sorted, i.e. prioritized,
according to their increasing overall scores, since lower scores
indicate a higher correlation with the reference genes and thus a
higher probability of being functionally related to (and hence more
likely involved in) the given phenotype.
Leave-one-out
We performed large-scale LOOCVs over all CNS-related
Mendelian disorders for both the spatially mapped expression
data from the HBA and the GEO dataset. For each known gene–
disease association, we constructed an artificial locus comprising
the disease gene itself and the N closest genes on both sides of the
chromosome (for N~50, N~100, N~200, and N~400), hence
containing at the most 2Nz1 genes. Then, we prioritized the
candidates from the artificial loci and verified the absolute rank
(Rg) and relative rank (Rrel
g ~Rg=number of candidates) of the
true disease gene g within the prioritized candidate list. For more
details, please see Supporting Text S1.
Candidate gene lists
To identify candidate genes (in terms of Entrez gene IDs)
residing between or at the markers flanking the mapped linkage
intervals, reported in the respective publications (see Table 2), we
used the UCSC Genome Browser [75].
Supporting Information
Table S1 List of GEO accessions of the ‘traditional’
microarray expression data set.
(PDF)
Table S2 Results of the leave-one-out tests for human
CNS-related OMIM phenotypes. Legend: N represents the
size of the artificial loci having a maximum of 2N+1 genes. The
average numbers of effective candidates with expression profiles
and the numbers of evaluated g–p pairs are shown. The observed
and expected numbers of g–p pairs, for which the true phenotype-
causing gene g ranks first, among the top ten and within the best
10% of the prioritized list, is reported along with the correspond-
ing P-values (one-tailed Fisher exact test). Significant P-values are
highlighted ( Pv0.05;   Pv0.01;    Pv0.001). Reference genes
(Ref.) were either taken from similar phenotypes (sim.), or from the
OMIM disease phenotype itself (dis.). {Results taken from [18];
artificial loci with N =400 have not been evaluated in our previous
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(PDF)
Table S3 Overlap of correct leave-one-out predictions
(over all CNS-related OMIM phenotypes) for reference
genes from similar phenotypes. Legend: N represents the
size of the artificial loci, having a maximum of 2N+1 genes. The
number of predictions with the true phenotype-causing gene g
ranking first, among the top ten and within the best 10% of the
prioritized list (see also Table S2, is reported for the Human Brain
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(PDF)
Table S4 Candidate gene prioritizations/predictions
for orphan FEB and GEFS+ loci. Legend: locus = orphan
FEB/GEFS+ locus; candidate_id/ symbol = Entrez gene ID and
symbol of the positional candidate; rank_HBA/ GEO = rank
among the prioritized positional candidates for the HBA/GEO
dataset; relRank_HBA/GEO = relative rank among the
prioritized positional candidates for the HBA/GEO dataset (rank
divided by number of candidates with expression data); avRel-
Rank_HBA+GEO = average relative rank, i.e. (relRank HBA
zrelRank GEO)=2 if the candidate has expression data in both
datasets, otherwise the average relative rank is taken as either
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